166 related articles for article (PubMed ID: 30651934)
1. Phase I/II clinical trial of the targeted chemotherapeutic drug, folate-tubulysin, in dogs with naturally-occurring invasive urothelial carcinoma.
Szigetvari NM; Dhawan D; Ramos-Vara JA; Leamon CP; Klein PJ; Ruple AA; Heng HG; Pugh MR; Rao S; Vlahov IR; Deshuillers PL; Low PS; Fourez LM; Cournoyer AM; Knapp DW
Oncotarget; 2018 Dec; 9(97):37042-37053. PubMed ID: 30651934
[TBL] [Abstract][Full Text] [Related]
2. Targeting folate receptors to treat invasive urinary bladder cancer.
Dhawan D; Ramos-Vara JA; Naughton JF; Cheng L; Low PS; Rothenbuhler R; Leamon CP; Parker N; Klein PJ; Vlahov IR; Reddy JA; Koch M; Murphy L; Fourez LM; Stewart JC; Knapp DW
Cancer Res; 2013 Jan; 73(2):875-84. PubMed ID: 23204225
[TBL] [Abstract][Full Text] [Related]
3. Enhancing the therapeutic range of a targeted small-molecule tubulysin conjugate for folate receptor-based cancer therapy.
Leamon CP; Reddy JA; Vlahov IR; Dorton R; Bloomfield A; Vetzel M; Klein PJ; Westrick E; Xu LC; Wang Y
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1151-1160. PubMed ID: 28451831
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous 5-azacitidine treatment of naturally occurring canine urothelial carcinoma: a novel epigenetic approach to human urothelial carcinoma drug development.
Hahn NM; Bonney PL; Dhawan D; Jones DR; Balch C; Guo Z; Hartman-Frey C; Fang F; Parker HG; Kwon EM; Ostrander EA; Nephew KP; Knapp DW
J Urol; 2012 Jan; 187(1):302-9. PubMed ID: 22099988
[TBL] [Abstract][Full Text] [Related]
5. DNMT1: an emerging target in the treatment of invasive urinary bladder cancer.
Dhawan D; Ramos-Vara JA; Hahn NM; Waddell J; Olbricht GR; Zheng R; Stewart JC; Knapp DW
Urol Oncol; 2013 Nov; 31(8):1761-9. PubMed ID: 22609058
[TBL] [Abstract][Full Text] [Related]
6. Comparative Gene Expression Analyses Identify Luminal and Basal Subtypes of Canine Invasive Urothelial Carcinoma That Mimic Patterns in Human Invasive Bladder Cancer.
Dhawan D; Paoloni M; Shukradas S; Choudhury DR; Craig BA; Ramos-Vara JA; Hahn N; Bonney PL; Khanna C; Knapp DW
PLoS One; 2015; 10(9):e0136688. PubMed ID: 26352142
[TBL] [Abstract][Full Text] [Related]
7. In vivo structural activity and optimization studies of folate-tubulysin conjugates.
Reddy JA; Dorton R; Dawson A; Vetzel M; Parker N; Nicoson JS; Westrick E; Klein PJ; Wang Y; Vlahov IR; Leamon CP
Mol Pharm; 2009; 6(5):1518-25. PubMed ID: 19630399
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive gene expression analysis of canine invasive urothelial bladder carcinoma by RNA-Seq.
Maeda S; Tomiyasu H; Tsuboi M; Inoue A; Ishihara G; Uchikai T; Chambers JK; Uchida K; Yonezawa T; Matsuki N
BMC Cancer; 2018 Apr; 18(1):472. PubMed ID: 29699519
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring,
Rossman P; Zabka TS; Ruple A; Tuerck D; Ramos-Vara JA; Liu L; Mohallem R; Merchant M; Franco J; Fulkerson CM; Bhide KP; Breen M; Aryal UK; Murray E; Dybdal N; Utturkar SM; Fourez LM; Enstrom AW; Dhawan D; Knapp DW
Mol Cancer Ther; 2021 Nov; 20(11):2177-2188. PubMed ID: 34433660
[TBL] [Abstract][Full Text] [Related]
10. Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue.
Leamon CP; Reddy JA; Vetzel M; Dorton R; Westrick E; Parker N; Wang Y; Vlahov I
Cancer Res; 2008 Dec; 68(23):9839-44. PubMed ID: 19047164
[TBL] [Abstract][Full Text] [Related]
11. Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.
Wouda RM; Hocker SE; Higginbotham ML
Vet Comp Oncol; 2018 Mar; 16(1):E52-E60. PubMed ID: 28799187
[TBL] [Abstract][Full Text] [Related]
12. Assessment of folate receptor expression and folate uptake in multicentric lymphomas in dogs.
Childress MO; Dhawan D; Leamon CP; Miller MA; Ramos-Vara JA; Naughton JF; Low PS; Knapp DW
Am J Vet Res; 2014 Feb; 75(2):187-94. PubMed ID: 24471755
[TBL] [Abstract][Full Text] [Related]
13. Identification of a naturally-occurring canine model for early detection and intervention research in high grade urothelial carcinoma.
Dhawan D; Ramos-Vara JA; Utturkar SM; Ruple A; Tersey SA; Nelson JB; Cooper BR; Heng HG; Ostrander EA; Parker HG; Hahn NM; Adams LG; Fulkerson CM; Childress MO; Bonney PL; Royce C; Fourez LM; Enstrom AW; Ambrosius LA; Knapp DW
Front Oncol; 2022; 12():1011969. PubMed ID: 36439482
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of satraplatin in dogs with spontaneously occurring malignant tumors.
Selting KA; Wang X; Gustafson DL; Henry CJ; Villamil JA; McCaw DL; Tate D; Beittenmiller M; Garnett C; Robertson JD
J Vet Intern Med; 2011; 25(4):909-15. PubMed ID: 21564292
[TBL] [Abstract][Full Text] [Related]
15. Toxicity of dolastatin 10 in mice, rats and dogs and its clinical relevance.
Mirsalis JC; Schindler-Horvat J; Hill JR; Tomaszewski JE; Donohue SJ; Tyson CA
Cancer Chemother Pharmacol; 1999; 44(5):395-402. PubMed ID: 10501913
[TBL] [Abstract][Full Text] [Related]
16. A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.
Foss FM; Parker T
Oncologist; 2018 Apr; 23(4):397-e30. PubMed ID: 29438091
[TBL] [Abstract][Full Text] [Related]
17. A Comparative Oncology Study of Iniparib Defines Its Pharmacokinetic Profile and Biological Activity in a Naturally-Occurring Canine Cancer Model.
Saba C; Paoloni M; Mazcko C; Kisseberth W; Burton JH; Smith A; Wilson-Robles H; Allstadt S; Vail D; Henry C; Lana S; Ehrhart EJ; Charles B; Kent M; Lawrence J; Burgess K; Borgatti A; Suter S; Woods P; Gordon I; Vrignaud P; Khanna C; LeBlanc AK
PLoS One; 2016; 11(2):e0149194. PubMed ID: 26866698
[TBL] [Abstract][Full Text] [Related]
18. A Nonselective Cyclooxygenase Inhibitor Enhances the Activity of Vinblastine in a Naturally-Occurring Canine Model of Invasive Urothelial Carcinoma.
Knapp DW; Ruple-Czerniak A; Ramos-Vara JA; Naughton JF; Fulkerson CM; Honkisz SI
Bladder Cancer; 2016 Apr; 2(2):241-250. PubMed ID: 27376143
[No Abstract] [Full Text] [Related]
19. Naturally-Occurring Invasive Urothelial Carcinoma in Dogs, a Unique Model to Drive Advances in Managing Muscle Invasive Bladder Cancer in Humans.
Knapp DW; Dhawan D; Ramos-Vara JA; Ratliff TL; Cresswell GM; Utturkar S; Sommer BC; Fulkerson CM; Hahn NM
Front Oncol; 2019; 9():1493. PubMed ID: 32039002
[TBL] [Abstract][Full Text] [Related]
20. An open-label dose escalation study evaluating tolerability and safety of a single 5-days course of temozolomide in dogs with advanced cancer.
Marconato L; Rohrer Bley C; Leone VF; Finotello R
Vet Comp Oncol; 2020 Dec; 18(4):838-842. PubMed ID: 32510792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
